Correlation Between Abivax SA and Medesis Pharma

Can any of the company-specific risk be diversified away by investing in both Abivax SA and Medesis Pharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Abivax SA and Medesis Pharma into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Abivax SA and Medesis Pharma SA, you can compare the effects of market volatilities on Abivax SA and Medesis Pharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Abivax SA with a short position of Medesis Pharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Abivax SA and Medesis Pharma.

Diversification Opportunities for Abivax SA and Medesis Pharma

0.77

Correlation Coefficient

Abivax SA  Medesis Pharma

Poor diversification

The 3 months correlation between Abivax and Medesis is 0.77. Overlapping area represents the amount of risk that can be diversified away by holding Abivax SA and Medesis Pharma SA in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Medesis Pharma SA and Abivax SA is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Abivax SA are associated (or correlated) with Medesis Pharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Medesis Pharma SA has no effect on the direction of Abivax SA i.e., Abivax SA and Medesis Pharma go up and down completely randomly.

Pair Corralation between Abivax SA and Medesis Pharma

Assuming the 90 days trading horizon Abivax SA is expected to under-perform the Medesis Pharma. But the stock apears to be less risky and, when comparing its historical volatility, Abivax SA is 2.25 times less risky than Medesis Pharma. The stock trades about -0.2 of its potential returns per unit of risk. The Medesis Pharma SA is currently generating about -0.08 of returns per unit of risk over similar time horizon. If you would invest  54.00  in Medesis Pharma SA on September 15, 2024 and sell it today you would lose (19.00) from holding Medesis Pharma SA or give up 35.19% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Abivax SA  vs.  Medesis Pharma SA

Abivax SA

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Abivax SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Medesis Pharma SA

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Medesis Pharma SA has generated negative risk-adjusted returns adding no value to investors with long positions. Even with weak performance in the last few months, the Stock's basic indicators remain relatively invariable which may send shares a bit higher in January 2025. The latest agitation may also be a sign of long-running up-swing for the enterprise retail investors.

Pair Trading with Abivax SA and Medesis Pharma

The main advantage of trading using opposite Abivax SA and Medesis Pharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Abivax SA position performs unexpectedly, Medesis Pharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medesis Pharma will offset losses from the drop in Medesis Pharma's long position.

The idea behind Abivax SA and Medesis Pharma SA pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.